Who We Are
Two Labs Blog
Two Labs Blog
Two Labs a Best Place to Work in Central Ohio
Michael Rowe Joins Two Labs as DSCSA (Serialization) Compliance Services Manager
What manufacturers need to know about Minnesota House Bill 400
New regulation requirements impacting your license
Doug Troy Joins Two Labs as New Chief Operating Officer
Two Labs Joins Global Celebration of Rare Disease Day
Current and Future Oncology Management in the United States
Innovative Access Agreements
Failure to Launch: Five key reasons that biosimilars have failed to gain traction in the US market
Two Labs Acquires Pennside Partners Ltd.
Everything You Need to Know About the DSCSA in 2018
Comparison of US and EU approaches to Oncology Management
Key Learnings on Pathways of Care
How a Trade Commercialization Team Makes Licensing Easier
Two Labs Hires Anita Dopkosky as Vice President of Specialty Pharmacy
Two Labs Acquires MKO Global Partners
How DSCSA Changes the Licensing Landscape for Third-Party Logistics
The Basics of Licensing: In & Out, Drug, & Facility
3 Entities That Can Change Your State Licensing Strategy
Consequences Pharmaceutical Companies Can Face for not Carrying the Correct State License and Being Noncompliant
Why Compendia is More Than Just a Price Book
Where do your Sales Reps turn when they have EHR issues?
Two Labs Marketing is Changing Its Name
Targeted agents indicated for autoimmune diseases
MKO Minute – Rise of Gene Therapy
Will lower cost therapies take share from legacy treatments?
Management and Budget Impact
7 Top Pharma Trends for 2017
MKO Minute – When Cures Become Commodities
Medical 3D Printing Breakthroughs Keep on Coming
Prescription Drugs: To Import or Not to Import?
NHS England Overhauls Access to Cancer Treatments
T-Cell Immunotherapy Market Predicted To Grow
British Pharma Industry Faces Challenges Post-Brexit
Is 3D Printing The Next Big Thing In Pharma?
Wearable Health Monitors & Apps-Transforming Health Care Delivery
Drug Development Clinical Trial Data – Public or Private?
Is Maine Right About Importing Prescription Drugs?
New Cancer Drugs Fuel Debate over Drug Testing Process
Adherence to Drug Regimens: Implications for Drug Developers
Is NICE Denying Patients the Best Treatments Available Today?
Do We Need Phase III Randomized Controlled Trials for EVERYTHING?
Defining Success in Clinical Trials: Is Learning Something Enough?
Breakthrough Therapy Opens Door to Streamlined Drug Development
Pharmaceutical Marketing Cutbacks, Doctors Getting Squeezed
Momentum for Biosimilars is Building. What’s Next?
Molecular Testing in Trouble from Medicare. Who’s on First?
Will Oncology and Pathology Unite on Molecular Testing?
NCI Improvements: Drug Development Opportunity for Pharma and Biotech
Orphan Diseases Open Opportunity for Pharma, Biotech Drug Developers
ASCO GU: Heads-Up for Biotech Drug Development in Kidney Cancer
FDA-Mixed Response to Proposed Faster Drug Development Pathway
FDA to Consider Faster Drug Development via Smaller Clinical Trials
ASCO GI Preview - Heads Up for GI Cancer Drug Development
Breast Cancer Drug Development - Targeting HER2 Activating Mutations
Welcome to Pharma & Biotech Today
Subscribe to Email Updates
Posts by Topic
Best Places to Work
Medical 3D Printing
Rare Disease Day
© 2019 TwoLabs, LLC
110 Riverbend Avenue, Suite 100 / Powell, Ohio 43065 / Phone: (614) 389-4004 / Fax: (866) 259-4324 / Email: